-
| ISIN | US33749P4081 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| PE Ratio | None |
|---|---|
| Target Price | 36 |
| Beta | 1.15 |
| Market Cap | 10M |
| Dividend Yield | None |
Entero Therapeutics, Inc. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It serves residential and small business, commercial and utility, technology and innovation, and hyperscale industries. The company is based in Edinburgh, United Kingdom with additional offices in Prague, Czechia; and Mississauga, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ENTO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026